Miriam Freimer, MD
Neurology · Columbus, OHNPI 1659455863
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $95,352 of the $104,872 with a category attached, or 90.9%. 8 manufacturers reported payments, led by UCB, Inc. at 52.4% of the total. Reporting peaked in 2024 at $39,993 and has fallen 82.5% since, to $7,012 in 2025. Among neurology clinicians in OH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 99 payments — averaging $1059.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$55K
- Argenx US, Inc.$23K
- AstraZeneca$11K
- UCB SA$11K
- Janssen Scientific Affairs, LLC$2K
- CSL Behring$2K
- plus $2K from 2 others
Across 322 payments — averaging $7546.54 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- UCB SA$1M
- Alnylam Pharmaceuticals Inc.$453K
- Amicus Therapeutics, Inc.$269K
- Janssen Research & Development, LLC$158K
- Catalyst Pharmaceuticals, Inc.$154K
- Takeda Pharmaceuticals U.S.A., Inc.$71K
- plus $296K from 8 others
What the payments were for
- Consulting fees$95,35291%
- Speaking & faculty fees$1,9502%
- Travel & lodging$4,8845%
- Food & beverage$2,6673%
- Education$200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 43 | $54,977 |
| Argenx US, Inc. | 24 | $22,623 |
| AstraZeneca | 5 | $10,735 |
| UCB SA | 21 | $10,644 |
| Janssen Scientific Affairs, LLC | 3 | $2,324 |
| CSL Behring | 1 | $1,950 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $1,600 |
| Alnylam Pharmaceuticals Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$104,872 in reported general payments places this provider in the 90th percentile of 702 neurology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FirdapseAmifampridine Phosphate | 21 | $1,108,483 |
| ZilbrysqZilucoplan Sodium | 25 | $1,028,653 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 40 | $805,565 |
| VyvgartEfgartigimod Alfa-Fcab | 12 | $529,049 |
| PanzygaImmun Glob G(Igg)-Ifas/Glycine | 13 | $164,808 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 14 | $52,218 |
| Mycophenolate Mofetil | 161 | $19,358 |
| Pyridostigmine Bromide | 117 | $10,516 |
| Pyridostigmine Bromide ErPyridostigmine Bromide | 14 | $6,047 |
| Albuterol Sulfate | 14 | $3,809 |
| Prednisone | 156 | $860 |
| Sodium Chloride0.9 % Sodium Chloride | 38 | $294 |
| Gabapentin | 27 | $203 |
| Tizanidine Hcl | 11 | $73 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| UCB, Inc.Zilbrysq | $54,977 | $1,028,65325 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $1,600 | $805,56540 claims |
| Argenx US, Inc.Vyvgart | $22,623 | $529,04912 claims |
| CSL BehringPrivigen | $1,950 | $52,21814 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 702 neurology providers in Ohio.
Other neurology in Columbus
- Kenneth MankowskiColumbus$1.4M
- Aaron BosterColumbus$1.2M
- Jacqueline NicholasColumbus$743K
- Geoffrey EubankColumbus$508K
- Jerry MendellColumbus$315K
- Andrew SmithColumbus$254K
- Douglas ScharreColumbus$191K
- Aristide MerolaColumbus$133K
- Allison JordanColumbus$98K
- Aram ZabetiCincinnati$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.